SKSharon Kandari

Sharon Kandari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sharon Kandari has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multicenter prospective real-world cohort study of direct oral anticoagulant use for venous thromboembolism prophylaxis in nephrotic syndrome

    by Priti Meena, Nitin Kumar, Sandip Kumar Panda, Sharon Kandari, Ganesh Srinivasa Prasad, Vinant Bhargava, Vikash Khandelia, Prashant Malviya, Nikunj Kishore Rout, Paromita Das, et al.

    Nephrotic syndrome (NS), especially when associated with severe hypoalbuminia, confers a high risk of venous thromboembolism (VTE). While low-molecular-wei

  • Open Access

    A Multicentric prospective Real-World Experience of Direct Oral Anticoagulants use in prophylaxis of Venous Thromboembolism in Nephrotic syndrome

    by Priti Meena, Nitin Kumar, Sandip Kumar Panda, Sharon Kandari, Ganesh Srinivasa Prasad, Vinant Bhargava, Vikash Khandelia, Prashant Malviya, Nikunj Kishore Rout, Paromita Das, et al.

    Introduction : Patients with nephrotic syndrome (NS), particularly with severe hypoalbuminia are at significantly increased risk for venous thromboembolism (VTE). Although vitamin K antagonists (VKAs) have traditionally been used for prophylaxis. Evidence supporting direct oral anticoagulants (DOACs) for primary prophylaxis in NS remains scarce, with a lack of prospective real-world data. Methods : We conducted a prospective multicentric cohort study across eight tertiary centers in India, enrolling adults (≥ 18 years) with NS and severe hypoalbuminemia (albumin < 2.4 g/dL for Membranous nephropathy; <2.0 g/dL for other etiologies). All patients received apixaban 5 mg once daily as primary VTE prophylaxis until albumin levels improved beyond 2.4 g/dL. The primary composite outcome included VTE occurrence and major or clinically significant bleeding events. Patients were followed until anticoagulation discontinuation. Results : A total of 212 patients were analyzed (mean age 36.9 ± 14.0 years, 52% male). Median proteinuria was 9.0 g/day and mean serum albumin 1.68 ± 0.49 g/dL; mean serum creatinine was 1.5 ± 0.54 mg/dL. Most patients were categorized as low (80%) or intermediate (20%) bleeding risk by GN tool. Membranous nephropathy was the most common etiology (45%). Immunosuppressive therapy included corticosteroids (81%), rituximab (25.9%), and cyclophosphamide (28.3%). The mean duration of apixaban therapy was 3 months. No venous or arterial thromboembolic events occurred, and minor bleeding was observed in 4 patients (3.5%), all resolving without transfusion or hospitalization. Overall apixaban was well tolerated. Conclusion : This large multicenter prospective study showed that apixaban prophylaxis appears safe, well-tolerated, and potentially effective in preventing VTE among high-risk NS patients. Larger randomized trials are needed to validate findings and optimize dosing, but current data support the rational integration of DOACs into NS thromboprophylaxis protocols.